L
Luminita Vida-Simiti
Publications - 4
Citations - 7069
Luminita Vida-Simiti is an academic researcher. The author has contributed to research in topics: Canakinumab & Medicine. The author has an hindex of 3, co-authored 3 publications receiving 4906 citations.
Papers
More filters
Journal ArticleDOI
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Paul M. Ridker,Brendan M. Everett,Tom Thuren,Jean G. MacFadyen,William Chang,Christie M. Ballantyne,Francisco H. Fonseca,Jose C. Nicolau,Wolfgang Koenig,Stefan D. Anker,John J.P. Kastelein,Jan H. Cornel,Prem Pais,Daniel Pella,Jacques Genest,Renata Cifkova,Alberto J. Lorenzatti,Tamás Forster,Zhanna Kobalava,Luminita Vida-Simiti,Marcus Flather,Hiroaki Shimokawa,Hisao Ogawa,Mikael Dellborg,Paulo Roberto Ferreira Rossi,Roland P.T. Troquay,Peter Libby,Robert J. Glynn +27 more
TL;DR: Antiinflammatory therapy targeting the interleukin‐1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid‐level lowering.
Journal ArticleDOI
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
Paul M. Ridker,Jean G. MacFadyen,Tom Thuren,Brendan M. Everett,Peter Libby,R J Glynn,Paul Ridker,Alberto J. Lorenzatti,Henry Krum,John Varigos,Peter Siostrzonek,Peter Sinnaeve,Francisco Antonio Helfenstein Fonseca,Jose C. Nicolau,Nina Gotcheva,Jacques Genest,Huo Yong,Miguel Urina-Triana,Davor Miličić,Renata Cifkova,Riina Vettus,Wolfgang Koenig,Stephan D Anker,Athanasios J. Manolis,Fernando Wyss,Tamás Forster,Axel Sigurdsson,Prem Pais,Alessandro Fucili,Hisao Ogawa,Hiroaki Shimokawa,Irina Veze,Birute Petrauskiene,Leon Salvador,John J.P. Kastelein,Jan H. Cornel,Tor Ole Klemsdal,Félix Medina,Andrzej Budaj,Luminita Vida-Simiti,Zhanna Kobalava,Petar Otasevic,Daniel Pella,Mitja Lainscak,Ki-Bae Seung,Patrick J. Commerford,Mikael Dellborg,Marc Y. Donath,Juey-Jen Hwang,Hakan Kultursay,Marcus Flather,Christie M. Ballantyne,Seth Bilazarian,William Chang,Cara East,Brendan Everett,Les Forgosh,Robert J. Glynn,Barry Harris,Monica Ligueros,Erin A. Bohula,Bindu Charmarthi,Susan Cheng,Sherry Chou,Jacqueline Danik,Graham McMahon,Bradley Maron,MingMing Ning,Benjamin Olenchock,Reena Pande,Todd Perlstein,Aruna D. Pradhan,Natalia Rost,Aneesh Singhal,Viviany Taqueti,Nancy Wei,Howard A. Burris,Angela Cioffi,Anne Marie Dalseg,Nilanjan Ghosh,Julie R. Gralow,Tina Mayer,Hope S. Rugo,Vance G. Fowler,Ajit P. Limaye,Sara Cosgrove,Donald Levine,Renato D. Lopes,John D. Scott,Robert Hilkert,Georgia Tamesby,Carolyn Mickel,Brian Manning,Julian Woelcke,Monique Tan,Sheryl Manfreda,Tom Ponce,Jane Kam,Ravinder Saini,Kehur Banker,Thomas Salko,Panjat Nandy,Ronda Tawfik,Greg O'Neil,Shobha Manne,Pravin Jirvankar,Shankar Lal,Deepak Nema,Jaison Jose,Rory Collins,Kent Bailey,Roger S. Blumenthal,Helen M. Colhoun,Bernard J. Gersh +113 more
TL;DR: The hypothesis-generating data suggest the possibility that anti-inflammatory therapy with canakinumab targeting the interleukin-1β innate immunity pathway could significantly reduce incident lung cancer and lung cancer mortality.
Journal ArticleDOI
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
Paul M. Ridker,Jean G. MacFadyen,Brendan M. Everett,Peter Libby,Tom Thuren,Robert J. Glynn,John J.P. Kastelein,Wolfgang Koenig,Jacques Genest,Alberto J. Lorenzatti,John Varigos,Peter Siostrzonek,Peter Sinnaeve,Francisco Antonio Helfenstein Fonseca,Jose C. Nicolau,Nina Gotcheva,Huo Yong,Miguel Urina-Triana,Davor Miličić,Renata Cifkova,Riina Vettus,Stephan D Anker,Athanasios J. Manolis,Fernando Wyss,Tamás Forster,Axel Sigurdsson,Prem Pais,Alessandro Fucili,Hisao Ogawa,Hiroaki Shimokawa,Irina Veze,Birute Petrauskiene,Leon Salvador,Jan H. Cornel,Tor Ole Klemsdal,Félix Medina,Andrzej Budaj,Luminita Vida-Simiti,Zhanna Kobalava,Petar Otasevic,Daniel Pella,Mitja Lainscak,Ki-Bae Seung,Patrick J. Commerford,Mikael Dellborg,Marc Y. Donath,Juey-Jen Hwang,Hakan Kultursay,Marcus Flather,Christie M. Ballantyne,Seth Bilazarian,William Chang,Cara East,Les Forgosh,Barry Harris,Monica Ligueros +55 more
TL;DR: The magnitude of hsCRP reduction following a single dose of canakinumab might provide a simple clinical method to identify individuals most likely to accrue the largest benefit from continued treatment, and suggest that lower is better for inflammation reduction with canakinUMab.
Journal ArticleDOI
Recovery of right ventricular function after intermediate-risk pulmonary embolism: results from the multicentre Pulmonary Embolism International Trial (PEITHO)-2.
Anna C. Mavromanoli,Stefano Barco,Walter Ageno,Hélène Bouvaist,Marianne Brodmann,Claudio Cuccia,Francis Couturaud,Claudia Dellas,Konstantinos Dimopoulos,Daniel Duerschmied,Klaus Empen,Pompilio Faggiano,A. Ferrari,Nazzareno Galiè,Marcello Galvani,Alexandre Ghuysen,Georgios Giannakoulas,Menno V. Huisman,David Jiménez,Matija Kozak,Nicolas Meneveau,Thomas Münzel,Massimiliano Palazzini,Antoniu Petris,Giancarlo Piovaccari,Aldo Salvi,Sebastian Schellong,Kai-Helge Schmidt,Franck Verschuren,Irene Schmidtmann,Gerrit Toenges,Frederikus A. Klok,J.A.F Abelaira Freire,Ibrahim Akin,Toni Anusic,D. Becker,Laurent Bertoletti,G Bettoni,Harald Binder,Regina A. Carels,Giuseppe Di Pasquale,Daniel Dürschmied,Iolanda Enea,Joachim H. Ficker,Sabine Genth-Zotz,Philippe Girard,Stanislav Gorbulev,Matthias Held,Lukas Hobohm,Stavros Konstantinides,Kai Kronfeld,Irene Lang,Mareike Lankeit,Walter Lehmacher,Concepcion Patricia Lopez Miguel,N. Bethencourt Martín,Guy Meyer,Roman Parežnik,Kurt Quitzau,Irinel Parepa,Purificación Ramírez Martín,Marc Philip Righini,Silviu Bogdan Todea,Adam Torbicki,Luca Valerio,Thomas Vanassche,Luminita Vida-Simiti,Anamaria Wolf-Pütz +67 more
TL;DR: In this paper , the temporal changes of right ventricular (RV) function in the cohort of a prospective multicentre study investigating if an early switch to oral anticoagulation in patients with intermediate-risk PE is effective and safe.